Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
BAX and prostate cancer are reported together in 2 articles.
Gene
BAX
- HGNC
- HGNC:959
150articles
150mentions
1variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 25colorectal cancer 15hepatocellular carcinoma 10lymphoma 10lung cancer 9ulcerative colitis 4inflammatory bowel disease 3leukemia 3
Reported variants (articles · ClinVar status)
Phenotype
Prostate cancer
218articles
218mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Novel triazoloquinazoline derivatives as VEGFR inhibitors: synthesis, cytotoxic evaluation and in silico studies.
PMID 39995350 | PMCID PMC11901504 | DOI 10.1080/17568919.2025.2468146 · Future medicinal chemistry · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BAX | “It significantly inhibited VEGFR-2 and altered gene expression, promoting BAX, P21, and P53 while downregulating BCL-2.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “RESEARCH DESIGN AND METHODS: All synthesized compounds were confirmed by spectroscopic methods and tested in vitro for their inhibitory activities against hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and prostate cancer (PC3) cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | breast cancer | “RESEARCH DESIGN AND METHODS: All synthesized compounds were confirmed by spectroscopic methods and tested in vitro for their inhibitory activities against hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and prostate cancer (PC3) cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | hepatocellular carcinoma | “RESEARCH DESIGN AND METHODS: All synthesized compounds were confirmed by spectroscopic methods and tested in vitro for their inhibitory activities against hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and prostate cancer (PC3) cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
Knockdown of CDK2AP1 in primary human fibroblasts induces p53 dependent senescence.
PMID 25785833 | PMCID PMC4365013 | DOI 10.1371/journal.pone.0120782 · PloS one · 2015 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BAX | “CDK2AP1 knockdown also resulted in increased mRNA levels of p53, p21, BAX and PUMA and p53 protein levels.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “CDK2AP1 overexpression was shown to inhibit growth, reduce invasion and increase apoptosis in prostate cancer cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CDK2AP1 | “Knockdown of CDK2AP1 in primary human fibroblasts induces p53 dependent senescence.” | 0.98 | hgnc_dict_v1 |
| gene | CDK2 | “Cyclin Dependent Kinase-2 Associated Protein-1 (CDK2AP1) is known to be a tumor suppressor that plays a role in cell cycle regulation by sequestering monomeric CDK2, and targeting it for proteolysis.” | 0.98 | hgnc_dict_v1 |